Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma

Cancer Investigation

Volumn 23, Issue 5, 2005, Pages 399-403

  Li, Xiao ^a   Ye, Da Feng ^a   Xie, Xing ^a   Chen, Huai Zeng ^a   Lu, Wei Guo ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CD4+CD25+ regulatory T cell; Immunosuppression; Ovarian carcinoma

Indexed keywords

CD4 ANTIGEN; CD69 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; PHYTOHEMAGGLUTININ;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

CARCINOMA; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, INTERLEUKIN-2; TUMOR CELLS, CULTURED;

EID: 24944519910     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-67142     Document Type: Article

References (15)

1. Taylor, D.D.; Bender, D.P.; Gercel-Taylor, C.; Stanson, J.; Whiteside, T.L. Modulation of TCR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. Br. J. Cancer 2001, 84 (12), 1624-1629.
2. Botti, C.; Seregni, E.; Ferrari, L.; Martinetti, A.; Bombardieri, E. Immunosuppressive factors: role in cancer development and progression. Int. J. Biol. Markers 1998, 13 (2), 51-69.
3. Mckallip, R.; Li, R.; Ladisch, S. Tumor gangliosides inhibit the tumor-specific immune response. J. Immunol. 1999, 163 (7), 3718-3726.
4. + immunoregulatory cells. J. Immunol. 2001, 167 (3), 1137-1140.
5. Sakaguchi, S.; Sakaguchi, N.; Asano, M.; Itoh, M.; Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): breakdown of single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155 (3), 1151-1164.
6. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 1998, 188 (2), 287-296.
7. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 2001, 193 (11), 1295-1301.
8. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001, 194 (6), 823-832.
9. +T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999, 163 (10), 5211-5218.
10. + T cell dependent immune defense of B 16 melanoma. Cancer Res. 2001, 61 (24), 8643-8646.
11. + T-regulatory cells and systemic collapse of antitumour immunity. Immunology 2001, 103 (4), 449-457.
12. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001, 61 (12), 4766-4772.
13. Woo, E.Y.; Yeh, H.; Chu, C.S.; Schlienger, K.; Carroll, R.G. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 2002, 168 (9), 4272-4276.
14. Wolf, A.M.; Wolf, D.; Steurer, M.; Gastl, G.; Gunsilius, E.; Grubeck-Loebenstein, B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 2003, 9 (2), 606-612.
15. Liyanage, U.K.; Moore, T.T.; Joo, H.G.; Tanaka, Y.; Herrmann, V. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 2002, 169 (5), 2756-2761.